Guerbet Yönetim

David Hale'un ücretlendirmesi Guerbet'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€33m
Mar 31 2024	n/a	n/a	€28m
Dec 31 2023	€1m	€470k	€24m
Sep 30 2023	n/a	n/a	-€9m
Jun 30 2023	n/a	n/a	-€42m
Mar 31 2023	n/a	n/a	-€42m
Dec 31 2022	€1m	€470k	-€41m
Sep 30 2022	n/a	n/a	-€14m
Jun 30 2022	n/a	n/a	€13m
Mar 31 2022	n/a	n/a	€23m
Dec 31 2021	€2m	€470k	€33m
Sep 30 2021	n/a	n/a	€33m
Jun 30 2021	n/a	n/a	€33m
Mar 31 2021	n/a	n/a	€26m
Dec 31 2020	€933k	€470k	€18m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 1.55M ), French pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 551.93K ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Hale (56 yo)

4.8yrs

Görev süresi

€1,481,777

Tazminat

Mr. David Hale served as Independent Director of Orpea SA since July 28, 2022 until January 2024. He has been Chief Executive Officer of Guerbet SA since January 1, 2020 and serves as its MD & GM. Mr. Hale...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hale	CEO, MD & GM	4.8yrs	€1.48m	Veri yok
Philippe Bourrinet	Chief Pharmacist	4.8yrs	€11.50k	Veri yok
Jerome Estampes	CFO and Senior VP of Business Development & Licensing	5.6yrs	Veri yok	Veri yok
Sarah Dayre	Senior VP of Technical Operations & Interim Chief Pharmacist	3.8yrs	Veri yok	Veri yok
Charlotte Bamiere	Director of Legal Affairs	8.8yrs	Veri yok	Veri yok
Christine Allard	Senior Vice President of Public Affairs & Corporate Communications	no data	Veri yok	Veri yok
Eva Ohlsson	Senior Vice President of Human Resources	no data	Veri yok	Veri yok
Jean-Francois Blanc	Senior Vice President of Interventional Imaging	3.8yrs	Veri yok	Veri yok
Francois Nicolas	Senior VP of R&D	7.2yrs	Veri yok	Veri yok
Valérie Brissart	Senior Vice President of Diagnostic Imaging	4.8yrs	Veri yok	Veri yok
Mathieu Elie	Senior Vice President of Commercial Operations - Asia-Pacific	4.8yrs	Veri yok	Veri yok
Gitte Hesselholt	Senior Vice President of Commercial Operations - Americas & EMEA	4.8yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: GBT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michel Guerbet	Honorary Chairman	no data	€18.96k	54.99% € 183.7m
Hugues Lecat	Chairman of the Board	less than a year	Veri yok	Veri yok
Claire Jouault-Massiot	Non-Independent Director	11.5yrs	€27.60k	Veri yok
Mark Fouquet	Non-Independent Director	10.5yrs	€27.60k	Veri yok
Didier Izabel	Independent Director	10.5yrs	€109.68k	Veri yok
Céline Lamort	Non-Independent Director	9.5yrs	€27.60k	Veri yok
Nicolas Louvet	Non-Independent Director	8.5yrs	€26.40k	Veri yok
Eric Guerbet	Non-Independent Director	7.5yrs	€27.60k	Veri yok
Jean-Sebastien Raynaud	Employee Director	4.1yrs	Veri yok	Veri yok
Olivier Fougère	Employee Director	3.7yrs	Veri yok	Veri yok
Marc Massiot	Non-Independent Director	3.5yrs	€20.40k	Veri yok
Carine Dagommer	Non-Independent Director	2.5yrs	€25.20k	Veri yok

7.5yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GBT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Guerbet Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Guerbet SA Announces Board Changes

Guerbet SA, Annual General Meeting, May 24, 2024

Guerbet Announces Management Appointments

Guerbet SA, Annual General Meeting, May 26, 2023

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet SA, Annual General Meeting, May 28, 2021

Recent updates

Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%

Guerbet SA to Report First Half, 2025 Results on Sep 25, 2025

Guerbet SA to Report Fiscal Year 2024 Results on Mar 27, 2025

Investor sentiment deteriorates as stock falls 20%

New major risk - Financial position

Guerbet SA Announces Board Changes

Is Guerbet (EPA:GBT) Using Too Much Debt?

Guerbet SA Provides Earnings Guidance for the Year 2024

Dividend of €0.50 announced

Price target increased by 22% to €36.38

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

New minor risk - Share price stability

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Price target increased by 8.4% to €20.68

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

Price target decreased to €23.94

Consensus forecasts updated

Price target decreased to €26.82

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Price target decreased to €30.90

Consensus forecasts updated

Price target decreased to €32.80

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Price target decreased to €31.55

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Price target decreased to €36.18

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings: Revenues in line with analyst expectations

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Price target increased to €33.75

Consensus forecasts updated

Upcoming dividend of €0.70 per share

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Full year 2020 earnings released

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

New 90-day low: €29.85

Analysts update estimates

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.65

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

New 90-day high: €33.10

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?